Clinical Research Service
Navigating the complexities of clinical research for rare diseases requires a partner with deep expertise and flexible, patient-centric approaches. Protheragen provides tailored investigator-initiated trial (IIT) and comprehensive clinical research solutions, designed to overcome the unique challenges of small patient populations, heterogeneous disease presentations, and complex regulatory pathways. This comprehensive suite of services ensures that innovative therapies for rare disease patients move efficiently from bench to bedside.
Overview of Clinical Research for Rare Diseases
Clinical research for rare diseases presents a distinct paradigm compared to more common conditions, characterized by small, geographically dispersed patient populations, often limited natural history data, and a high degree of unmet medical need. Successful research demands innovative trial designs, such as adaptive protocols, and close collaboration with patient advocacy groups. The regulatory environment, while offering incentives like rare drug designation, requires precise strategy and communication. Ultimately, the goal is to generate robust evidence for diagnostic and therapeutic development despite inherent logistical and methodological hurdles, accelerating access to novel interventions for patients.
Fig.1 Randomized studies incorporating self-control include case-crossover, N-of-1, delayed treatment initiation, and early withdrawal designs. (Li, Y., and Izem, R., 2022) Challenges and Solutions in Rare Disease Clinical Research
Conducting clinical research in rare diseases is fraught with specific obstacles, from patient identification to regulatory uncertainty. Our targeted solutions are engineered to address these critical pain points directly and effectively.
| Item | Challenges | Solutions |
|---|---|---|
| Patient Recruitment | Extremely small, globally dispersed populations; difficult diagnosis and referral pathways. | Leverage of established global investigator networks and deep partnerships with patient advocacy organizations; implementation of innovative digital outreach and pre-screening strategies. |
| Trial Design & Endpoints | Lack of validated endpoints; high disease heterogeneity; placebo-controlled trials may be unethical/unfeasible. | Expertise in innovative designs (adaptive, basket, N-of-1); utilization of historical controls and surrogate endpoints; development of novel biomarker and PRO strategies. |
| Operational Logistics | Studies often involve numerous, low-enrolling sites across multiple countries and complex clinical management. | Centralized, experienced project management; utilization of decentralized clinical trial (DCT) components and mobile technologies; streamlined site initiation and support. |
| Regulatory Strategy | Evolving and sometimes unclear regulatory pathways for ultra-rare conditions; navigating orphan drug designations. | Early and proactive regulatory consulting; development of compelling evidence packages for agency meetings (e.g., INTERACT, PRE-IND); strategic preparation of orphan drug designation applications. |
| Data & Evidence Generation | Limited natural history data; statistical challenges with small sample sizes. | Advanced biostatistical planning; robust data collection, including Real-World Evidence (RWE) integration; comprehensive data management and curation. |
Our Services
Built upon a foundation of deep scientific expertise in rare disease pathophysiology and years of operational experience, Protheragen delivers agile, dedicated clinical research services. Our solution combines strategic regulatory insight with hands-on execution, ensuring each study is both scientifically rigorous and operationally feasible. We are committed to advancing rare disease research through tailored partnerships that prioritize customer needs and clear outcomes.
Comprehensive Clinical Research Services for Rare Diseases
Protheragen delivers end-to-end clinical research solutions tailored to the unique challenges of rare diseases, encompassing both investigator-initiated trials (IIT) and industry-sponsored trials (IST). Supports academic sponsors and biopharmaceutical partners alike in navigating the complexities of small patient populations, heterogeneous disease presentations, and limited natural history data. Provides strategic and operational expertise from early concept through final study close-out, ensuring rigorous scientific standards and regulatory alignment.
Investigator Initiated Trial (IIT) Services
Facilitating investigator-driven research with dedicated operational, regulatory, and analytical support, our investigator-initiated trials (IITs) services enable academic and clinical researchers to transform scientific hypotheses into executable, high-quality trials for rare diseases.
By Workflow
Study Design & Protocol Development
Collaborates with investigators to craft scientifically robust and operationally feasible protocols, incorporating rare-disease-specific endpoints, meaningful biomarker strategies, and statistical methods appropriate for small sample sizes and potential patient heterogeneity.
Regulatory & Ethics Submission
Manages the full lifecycle of regulatory and ethics committee submissions, including informed consent documents, investigator brochures, and local regulatory packages, while navigating country-specific requirements unique to rare disease research.
Site Activation & Patient Recruitment
Accelerates site initiation through feasibility assessments, customized site agreements, and targeted patient recruitment strategies leveraging rare disease registries, patient advocacy groups, and multi-channel outreach efforts.
Conducts risk-based and remote monitoring activities with adaptive oversight intensity, ensuring data accuracy and patient safety while accommodating slow enrollment and geographically dispersed rare disease populations.
Data Management & Biostatistical Analysis
Designs rare-disease-optimized case report forms and data validation rules, then applies advanced statistical modeling techniques, including Bayesian methods, propensity scores, and longitudinal analyses for small or unevenly distributed datasets.
Medical Writing & Publication Support
Prepares clinical study reports, manuscript drafts, conference abstracts, and slide decks to ensure timely dissemination of findings, with particular attention to describing rare disease natural history and interpreting novel endpoints.
Advanced Therapy Investigational Platforms for IIT
Protheragen supports investigator-initiated research across a broad range of therapeutic modalities tailored to the underlying mechanisms of rare diseases. We provide operational and regulatory expertise to navigate modality-specific challenges such as viral vector manufacturing, oligonucleotide stability, blood-brain barrier penetration, and chronic infusion protocols. The following therapeutic modalities are fully supported for IITs in rare diseases:
- Gene Therapy: Supports viral and non-viral gene delivery, gene editing, and mRNA-based approaches for rare genetic disorders requiring protein restoration or correction.
- Oligonucleotide Therapeutics: Supports antisense oligonucleotides (ASOs), RNA interference (RNAi, siRNA), and other short nucleic acid modalities for rare diseases involving splicing defects, gain-of-function mutations, or targeted gene silencing.
- Protein and Antibody Therapies: Supports enzyme replacement therapy, protein replacement therapy, monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) for rare metabolic, immune-mediated, and signaling pathway disorders.
- Small Molecule Therapy: Supports pharmacological chaperones, substrate reduction therapy, and other small molecule approaches targeting rare disease pathways.
- Cell Therapy: Supports autologous and allogeneic cell-based approaches for rare hematologic, immunologic, and degenerative disorders.
- Other Emerging Modalities: Supports additional or novel therapeutic platforms as required by specific rare disease targets.
Industry Sponsored Trial (IST) Services
Providing full-spectrum operational and strategic support for biopharmaceutical sponsors conducting rare disease clinical research, our services adapt to both workflow-based and management-based service models to match sponsor needs and development stage.
- By Workflow
-
Phase I Clinical Trial
Designs and executes first-in-human and proof-of-concept studies in rare disease populations, focusing on safety, tolerability, pharmacokinetics, and early pharmacodynamic signals while addressing challenges of patient availability and dose-escalation feasibility.
-
Phase II Clinical Trial
Implements dose-ranging and early efficacy trials with adaptive designs, seamless transitions, and meaningful surrogate or clinical endpoints that can capture treatment effects in small cohorts with heterogeneous disease progression.
-
Phase III Clinical Trial
Executes pivotal registrational trials with rigorous site oversight, centralized endpoint adjudication, long-term follow-up planning, and robust statistical strategies that account for potential dropout rates and variable baseline characteristics in rare diseases.
-
Phase IV Clinical Trial
Manages post-approval commitment studies, long-term safety surveillance, and real-world evidence generation for marketed rare disease therapies, including observational registries and patient-reported outcome collections for ongoing assessment.
- By Management
-
Medical & Clinical Strategy Services
Shapes development pathways, target product profiles, and clinical trial designs that align with underlying rare disease biology, natural history data, and clinically meaningful outcome measures accepted by health authorities.
-
IND/NDA/BLA Application Strategy Services
Prepares comprehensive regulatory packages, briefing documents, and responses to health authority queries, including integrated summaries of safety and efficacy tailored to rare disease data packages with smaller datasets.
-
Produces high-quality clinical documents, including protocols, investigator brochures, clinical study reports, and submission-ready narratives that clearly present rare disease trial results and their clinical significance.
-
Site Management & Patient Recruitment Services
Oversees site selection, feasibility assessments, study activation, and ongoing site performance, coupled with patient identification strategies through disease registries and genetic testing databases.
-
Data Management & Statistical Analysis Services
Builds validated clinical databases with custom edit checks, performs longitudinal and rare-disease-specific statistical analyses, and handles missing data, small subgroups, and multiple comparisons using prespecified methods.
-
Provides real-time safety and efficacy review, protocol deviation assessment, eligibility confirmation, and medical decision support throughout the trial, with particular vigilance for rare adverse events and disease-specific complications.
-
Safety & Pharmacovigilance Services
Collects, processes, and analyzes adverse events and serious adverse events, expedites reporting requirements, and develops risk management plans that address unique safety concerns in small, often medically vulnerable patient populations.
-
Implements risk-based quality systems, audit-ready documentation, and corrective action plans across all study phases, with quality indicators tailored to the lower enrollment volumes and extended timelines typical of rare disease trials.
-
Coordinates cross-functional teams, integrated timelines, budget tracking, and vendor oversight to ensure seamless trial execution, with proactive contingency planning for recruitment delays or site challenges in rare disease settings.
-
Post-Marketing Study Services
Designs and manages observational registries, long-term extension protocols, patient-reported outcome studies, and other post-approval commitments to generate ongoing safety and effectiveness data for marketed rare disease treatments.
Disease Areas of Focus
Protheragen's clinical research solutions span a broad spectrum of rare conditions, including but not limited to rare neurological disorders, neuromuscular diseases, inherited metabolic disorders, rare cancers and hematologic conditions, pediatric rare diseases, and rare autoimmune/inflammatory conditions. We apply our specialized knowledge to tailor strategies that address the specific pathophysiology, patient population, and clinical outcome assessment needs of each unique disease.
Why Partner with Us?
- Dedicated Rare Disease Expertise: Our team comprises scientists and project managers who specialize exclusively in rare diseases, ensuring a profound understanding of both scientific and practical challenges.
- Integrated, End-to-End Support: From initial IIT strategy to regulatory filing support, we offer a seamless, unified service model that increases efficiency and accelerates timelines.
- Flexible Partnership Models: Offers customized engagement structures ranging from full-service trial management to functional support for biostatistics, medical writing, or site monitoring.
- Balance of Quality and Efficiency: Combines rigorous quality standards with optimized operational workflows to ensure timely delivery of reliable and compliant clinical data.
Contact Us
Advancing rare disease research demands a specialized partner equipped to navigate its unique complexities with scientific rigor and operational excellence. Protheragen is committed to providing the tailored, comprehensive clinical research services necessary to transform promising science into tangible hope for patients. To discuss how we can support your specific clinical research program, please contact our team of experts.
Reference
- Li, Yimei, and Rima Izem. "Novel clinical trial design and analytic methods to tackle challenges in therapeutic development in rare diseases." Annals of translational medicine 10.18 (2022): 1034.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.